ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications

Area of Science:

• Genetics and Molecular Biology
• Cardiovascular Research

Background:

• Cardiovascular diseases (CVDs) are a major global health concern.
• Long non-coding RNAs (lncRNAs) play a role in cardiovascular pathophysiology.
• Antisense Non-coding RNA in the INK4 Locus (ANRIL) is linked to the 9p21 CVD-associated locus.

Purpose of the Study:

• To systematically review ANRIL dysregulation in seven major cardiovascular conditions.
• To elucidate ANRIL's isoform-specific mechanisms in disease progression.
• To explore ANRIL's potential role in cardiac hypertrophy.

Main Methods:

• Systematic review of existing literature on ANRIL and cardiovascular diseases.
• Analysis of ANRIL expression patterns and functional mechanisms.
• Integration of recent research findings on ANRIL's role in cardiovascular pathophysiology.

Main Results:

• ANRIL expression is dysregulated across seven major cardiovascular conditions.
• Distinct linear and circular ANRIL isoforms exhibit specific functional roles.
• Emerging evidence suggests ANRIL involvement in cardiac hypertrophy.

Conclusions:

• ANRIL is a significant factor in the pathogenesis of diverse cardiovascular disorders.
• ANRIL isoforms present distinct mechanisms contributing to disease progression.
• ANRIL holds potential as a therapeutic target and biomarker for CVDs.